Phase I study to assess the pharmacokinetics and the effect on cardiac repolarization of amrubicin and amrubicinol in patients with advanced solid tumors

[1] Hanada M(1998)A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex Jpn J Cancer Res 89 1229-1238

[2] Mizuno S(1989)Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts Jpn J Cancer Res 80 69-76

[3] Fukushima A(1998)Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells Jpn J Cancer Res 89 1067-1073

[4] Saito Y(1980)Inhibition of human ovarian cancer colony formation by adriamycin and its major metabolites Cancer Res 40 4109-4112

[5] Noguchi T(1988)Uptake and intracellular distribution of doxorubicin metabolites in B-lymphocytes of chronic lymphocytic leukemia Cancer Res 48 503-506

[6] Yamaoka T(1992)Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture Cancer Chemother Pharmacol 30 51-57

[7] Morisada S(2010)Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer J Clin Oncol 28 2598-2603

[8] Yanagi Y(2011)Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy J Clin Oncol 29 287-293

[9] Nogushi T(2011)Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive-stage small cell lung cancer—EORTC 08062 Eur J Cancer 47 2322-2330

[10] Kashiwazaki Y(2006)Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer Cancer Chemother Pharmacol 57 282-288

[1] Hanada M(1998)A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex Jpn J Cancer Res 89 1229-1238

[2] Mizuno S(1989)Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts Jpn J Cancer Res 80 69-76

[3] Fukushima A(1998)Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells Jpn J Cancer Res 89 1067-1073

[4] Saito Y(1980)Inhibition of human ovarian cancer colony formation by adriamycin and its major metabolites Cancer Res 40 4109-4112

[5] Noguchi T(1988)Uptake and intracellular distribution of doxorubicin metabolites in B-lymphocytes of chronic lymphocytic leukemia Cancer Res 48 503-506

[6] Yamaoka T(1992)Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture Cancer Chemother Pharmacol 30 51-57

[7] Morisada S(2010)Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer J Clin Oncol 28 2598-2603

[8] Yanagi Y(2011)Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy J Clin Oncol 29 287-293

[9] Nogushi T(2011)Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive-stage small cell lung cancer—EORTC 08062 Eur J Cancer 47 2322-2330

[10] Kashiwazaki Y(2006)Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer Cancer Chemother Pharmacol 57 282-288